3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
14
Rectal Neoplasms
5
Neoplasm Metastasis
5
Cholangiocarcinoma
4
Stomach Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Biliary Tract Neoplasms
3
Adenocarcinoma Of Esophagus
3
Ovarian Neoplasms
2
Neoplasms
2
Gastrointestinal Neoplasms
2
Gallbladder Neoplasms
2
Esophageal Neoplasms
2
Recurrence
1
Pathologic Complete Response
1
Lung Neoplasms
1
Gastroesophageal Adenocarcinoma
1
Endometrial Neoplasms
1
Disease Progression
1
Central Nervous System Neoplasms
1
Carcinoma, Basal Cell
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Adenocarcinoma of the Lower Rectum
1
Adenocarcinoma
1
Interventions
Cyclophosphamide
25
fludarabine
19
Dexamethasone
17
pembrolizumab
13
Rituximab
12
venetoclax
9
Lenalidomide
9
Gemcitabine
9
Etoposide
9
pomalidomide
8
Vincristine
7
glofitamab
6
fludarabine phosphate
6
carfilzomib
6
Temozolomide
6
obinutuzumab
5
daratumumab
5
Prednisone
5
Nivolumab
5
Doxorubicin
5
Cisplatin
5
Calcium Dobesilate
5
Bortezomib
5
zanubrutinib
4
selinexor
4
Immunotherapy, Adoptive
4
Cytarabine
4
Carboplatin
4
Azacitidine
4
ruxolitinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Folfox protocol
×
90 days
×
Clear all
NCT06475352
2026-04-23
FUDOSE
UNICANCER
Phase 2
Recruiting
400 enrolled